Status:
TERMINATED
The Effects of GABA Enhancing Medications on Individuals Addicted to Cocaine - 3
Lead Sponsor:
Yale University
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Cocaine Abuse
Cocaine-Related Disorders
Eligibility:
All Genders
18-45 years
Phase:
NA
Brief Summary
Gamma-aminobutyric acid (GABA) is a type of neurotransmitter, which is a chemical that transmits information within and from the brain to all parts of the body. By lowering the level of another neurot...
Detailed Description
GABA is an inhibitory neurotransmitter that is found primarily in the brain. High GABA levels result in low levels of dopamine, another neurotransmitter that is the brain's "feel good" chemical and wh...
Eligibility Criteria
Inclusion
- Meets DSM-IV criteria for cocaine dependence
- History of smoked or intravenous cocaine use on average of at least once a week over a 6 month period
- Positive urine test for cocaine
- No current medical problems
- Normal electrocardiogram
- If female, willing to use contraception throughout the study
Exclusion
- Seeking treatment for cocaine dependence
- Current major psychiatric illness, including mood disorder, psychotic disorder, or anxiety disorder
- Current dependence on alcohol or any drugs other than cocaine or nicotine
- History of major medical illness, including liver disease, suspected or known cancer, thrombophlebitis, or other medical conditions that are considered unsafe for study participants by the investigator
- Known allergy to study medications
- Pregnant or breastfeeding
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2006
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT00142883
Start Date
September 1 2004
End Date
September 1 2006
Last Update
July 8 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA Connecticut Healthcare System
West Haven, Connecticut, United States, 06516